Drug Trial Radar · NCT05658692
Platform Adaptive Embedded Trial for Acute Respiratory Distress Syndrome
Last checked: Nov 20, 2026Latest source record: Dec 21, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
1,000
Planned (sponsor's estimate)
Start
Oct 1, 2022
Primary completion
Oct 2023
Study completion Dec 2023
Sponsor
- Lead sponsor
- Second Affiliated Hospital, Zhejiang University, School of MedicineAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Renmin Hospital of Wuhan University; The Second Affiliated Hospital of Harbin Medical University; West China Hospital; The First Affiliated Hospital of Zhengzhou University; Peking Union Medical College Hospital; Union Hospital, Tongji Medical College, Huazhong University of Science and Technology; Fudan University; Guangdong Provincial People's Hospital; Ningbo No. 1 Hospital; Taizhou Hospital of Zhejiang Province affiliated to Wenzhou Medical University
- First posted
- Dec 21, 2022
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Platform adaptive embedded trial for acute respiratory distress syndrome (PETARDS) is a randomized, embedded, multifactorial, adaptive platform trial for ARDS. The study aimed to assess the impact of multiple interventions on outcomes in patients with ARDS admitted to the ICU.
Conditions
- Acute Respiratory Distress Syndrome
Interventions
protective ventilationDevice
Patients with moderate to severe ARDS received ventilation treatment according to predicted body weight(PBW) and controlled plateau pressure.
prone position ventilationBehavioral
patients with moderate to severe ARDS who don't have contraindications were given prone ventilation for over 12 hours.
glucocorticoid therapyDrug
Dexamethasone: Patients received intravenous dexamethasone 20 mg daily from days 1 to 5, reduced to 10 mg daily from days 6 to 10. Hydrocortisone:For septic ARDS patients, 50 mg of hydrocortisone was given as an intravenous bolus every 6 hours for 7 days; For patients with COVID-19-related ARDS, The corticosteroid field randomized participants to a fixed 7-day period of intravenous hydrocortisone (50 mg or 100 mg every 6 hours).
restrictive fluid resuscitationOther
1. without other organ dysfunction patients: Minimize fluid was given; 2. other ARDS patients: In the resuscitation phase, controlled fluid replacement combined with vasoactive drugs was given; multiple measures were taken, like lactate and so on, to utilizedto guide fluid resuscitation therapy; diuretics or diuretics in combination with albumin to achieve fluid balance.
Thymosin AlphaBiological
People received thymosin Alpha subcutaneous injections, twice a week.
Muscle relaxant therapyDrug
Deep sedation combined with intermittent bolus injection of muscle relaxant or deep sedation combined with continuous infusion of muscle relaxant
Integrated Chinese and Western Medicine TreatmentOther
1. ventilation; 2. conventional western medicine treatment; 3. Chinese herbal medicine(Determining medication based on syndrome differentiation)
statin therapyDrug
1. Simvastatin: 80mg qd po for not more than 28days; 2. Rosuvastatin: 20mg qd po (40mg for the first time) for 28days or 3 days after transfer out of the ICU, or the patient died.
anti-infective treatmentCombination product
According to "Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021".
Extracorporeal Membrane Oxygenation(ECMO)Device
1. For severe ARDS patients with refractory hypoxemia within 7 days of onset; 2. (Inspiratory oxygen concentration) ≥ 0.80, tidal volume 6ml/kg (PBW), positive end-expiratory pressure \[PEEP\] ≥ 10 cmH2O; 3. V-V Model.
stem cell therapyGenetic
A single injection of bone marrow stem cells, doses of 1, 5, 10\*106 cells/kg was taken according to the previous clinical studies.
Sedative analgesia/muscle relaxant therapyDrug
Deep sedation combined with intermittent bolus injection of muscle relaxant or deep sedation combined with continuous infusion of muscle relaxant
inotropes therapyDrug
According to "Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021".
Vasoactive drug therapyDrug
According to "Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021".
Primary outcomes
What the sponsor says the trial is designed to measure.
- ventilator-free daysTime frame: within 28 days
Locations
11 sites in 1 country. Site status is shown where the registry gives one.
Peking Union Medical College Hospital
Beijing, China · Recruiting
West China Hospital,Sichuan University
Chengdu, China · Recruiting
Guangdong Provincial People's Hospital
Guangdong, China · Recruiting
The Second Affiliated Hospital of Harbin Medical University
Harbin, China · Recruiting
Lanxi People's Hospital
Lanxi, China · Recruiting
Ningbo First Hospital
Ningbo, China · Recruiting
Zhognshang hospital, Fudan University
Shanghai, China · Recruiting
Taizhou Hosptial of Zhejiang Province
Taizhou, China · Recruiting
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, China · Recruiting
Wuhan University Renmin Hospital
Wuhan, China · Recruiting
The First Affiliated Hospital of Zhengzhou University
Zhengzhou, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.